These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dysplastic nevus--risk factor or disguise for melanoma. Dediol I; Bulat V; Zivković MV; Marković BM; Situm M Coll Antropol; 2011 Sep; 35 Suppl 2():311-3. PubMed ID: 22220461 [TBL] [Abstract][Full Text] [Related]
7. Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi. Rauwerdink DJW; Roach REJ; Etty MA; Kukutsch NA; van Doorn R Br J Dermatol; 2018 Oct; 179(4):997-998. PubMed ID: 29704460 [No Abstract] [Full Text] [Related]
8. Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanoma. Clark WH; Tucker MA Hum Pathol; 1998 Jan; 29(1):8-14. PubMed ID: 9445128 [No Abstract] [Full Text] [Related]
9. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? Skender-Kalnenas TM; English DR; Heenan PJ J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345 [TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma: treatments emerging, but early detection is still key. Masci P; Borden EC Cleve Clin J Med; 2002 Jul; 69(7):529, 533-4, 536-8 passim. PubMed ID: 12109636 [TBL] [Abstract][Full Text] [Related]
11. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Elder DE; Clark WH; Elenitsas R; Guerry D; Halpern AC Semin Diagn Pathol; 1993 Feb; 10(1):18-35. PubMed ID: 8506414 [TBL] [Abstract][Full Text] [Related]
12. The role of atypical mole syndrome and cutaneous naevi in the development of melanoma. Easton D Cancer Surv; 1996; 26():237-49. PubMed ID: 8783577 [No Abstract] [Full Text] [Related]
15. Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control study. Stierner U; Augustsson A; Rosdahl I; Suurküla M Melanoma Res; 1992; 1(5-6):367-75. PubMed ID: 1422192 [TBL] [Abstract][Full Text] [Related]
16. Trajectories of premalignancy during the journey from melanocyte to melanoma. Colebatch AJ; Scolyer RA Pathology; 2018 Jan; 50(1):16-23. PubMed ID: 29132722 [TBL] [Abstract][Full Text] [Related]